Harun Muğlu

17PUBLICATIONS
117CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Models of care and place of birthChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 26, 2026
Efficacy and Tolerability of Pazopanib in Elderly Patients with Advanced Soft Tissue Sarcoma: A Multicentre Real-World Study from Turkey.

|Jun 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

|May 04, 2026
Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

|May 04, 2026
A Novel Biological Index for Predicting Neoadjuvant Treatment Response in HER2-Positive Breast Cancer: The Tumor-Immune-Proliferation-Inflammation (TIPI) Score.

|Mar 28, 2026
Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study.

Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

Pageof 3

Frequent Collaborators

13 joint publications

Ahmet Bilici

7 joint publications

Özgür Açıkgöz

7 joint publications

Jamshid Hamdard

6 joint publications

Mehmet Haluk Yücel